Odefsey tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F4F6B
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $164,455
Award facts
- Contract value 100% obligated
- $164,455.42 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $164,455.42 to AmerisourceBergen Drug Corp for the supply of Odefsey Tablet UU 30s, a pharmaceutical product. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of January 27, 2026, and was competitively awarded with no set-aside designation. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at up to $999,999,999.00 through December 2026. This comprehensive IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, and specialized medical commodities across multiple therapeutic domains.
AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc. (which operates under the AmerisourceBergen brand name), is a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The company serves as a critical vendor for federal medical procurement, with the performance location for this delivery order listed in Conshohocken, PA. AmerisourceBergen's federal contract portfolio demonstrates its extensive capability to fulfill government medical supply requirements through open competition, serving customers including the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The parent company, Cencora, Inc., also holds a significant IDC with DLA valued at up to $999,999,999.00 through December 31, 2031, further supporting the company's role as a primary pharmaceutical supplier for the Department of Defense healthcare infrastructure.
Quick answers
Who was awarded contract SPE2DR26F4F6B?
SPE2DR26F4F6B was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 26, 2026.
How much is contract SPE2DR26F4F6B worth?
The government has obligated $164,455 on SPE2DR26F4F6B.
Is contract SPE2DR26F4F6B an order under another contract?
Yes. SPE2DR26F4F6B is a delivery order under SPE2DR25D3012, an indefinite delivery contract.
Was contract SPE2DR26F4F6B competed?
The extent of competition for SPE2DR26F4F6B was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award